Latest Cell Engineering and Company News

EMPOWERING THE DEVELOPMENT OF BIOPHARMACEUTICALS

NEWS & press RELEASES

Press Releases

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies

The USPTO Issues a Patent to Cellular Engineering Technologies for Producing a Safer Induced Pluripotent Stem Cell

The patent awards Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize induced pluripotent stem cells that are...

Cellular Engineering Technologies Receives Exclusivity to Use John Paul II Medical Research Institute’s Immortalized Human Stem Cells for Commercial Bio-Production Applications

The exclusive right grants Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize next generation bio-production of recombinant...

Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement.

DUBLIN, Ireland and Coralville, Iowa, 17 August 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational...

Subscribe To Our Newsletter

A short message on why the visitor should subscribe to the newsletter and what they are likely to read about

Subscribe Now

Products

Featured Product

iPSC Solutions

Research Solutions

IPSC Solutions

Growth Factors

Research Solutions

Product

iPSC Solutions

Research Solutions

Featured Product

EMPOWERING THE DEVELOPMENT OF BIOPHARMACEUTICALS

NEWS & press RELEASES

Press Releases

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies

The USPTO Issues a Patent to Cellular Engineering Technologies for Producing a Safer Induced Pluripotent Stem Cell

Cellular Engineering Technologies Receives Exclusivity to Use John Paul II Medical Research Institute’s Immortalized Human Stem Cells for Commercial Bio-Production Applications

Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement.

Subscribe To Our Newsletter

Publications that cite CET products:

Reversal of Pulmonary Fibrosis: Human Umbilical Mesenchymal Stem Cells from Wharton's Jelly versus Human-Adipose-Derived Mesenchymal Stem Cells.

Development of hydrogel-based composite scaffolds containing eggshell particles for bone regeneration applications.

Exosomes derived from human adipose-derived stem cells alleviate hepatic ischemia-reperfusion (I/R) injury through the miR-183/ALOX5 axis.

Texturization of polycrystalline titanium surfaces after low-energy ion-beam irradiation: Impact on biocompatibility

Naïve pluripotent-like characteristics of non-tumorigenic Muse cells isolated from human amniotic membrane

Decellularized liver hydrogel enhances cell engraftment in orthotopic hepatocyte transplantation by promoting cell-cell interaction and angiogenesis.

Relationship between clock gene expression and CYP2C19 and CYP3A4 with benzodiazepines.

Hydroxyapatite Nanocoating on Calcium Peroxide Microparticles for Sustained Oxygen Release

Studio preclinico di allograft bioingegnerizzati da diaframma umano decellularizzato per la rigenerazione del muscolo scheletrico. Patella

Effect of methamphetamine on clock genes and drug-metabolizing enzyme expression.

Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice.

Effect of Metformin on Human Mesenchymal Stem Cells

Follow us:

Contact

Products

E-Commerce

Quick Links